Deprecated: mysql_connect(): The mysql extension is deprecated and will be removed in the future: use mysqli or PDO instead in /home/content/15/3443015/html/receptopharm/newsroom/data.php on line 12

Deprecated: Function split() is deprecated in /home/content/15/3443015/html/receptopharm/newsroom/display.php on line 19
ReceptoPharm // Newsroom // Nutra Pharma Reports Final Results for ReceptoPharm's RPI-78M in Multiple Sclerosis Animal Model
ReceptoPharm  
Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
 
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
 
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More

Newsroom

Nutra Pharma Reports Final Results for ReceptoPharm's RPI-78M in Multiple Sclerosis Animal Model
December 20, 2005

Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced the completion of studies using RPI-78M in an animal model of Multiple Sclerosis (MS). RPI-78M is the lead drug candidate of Nutra Pharma's holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating MS.

EAE (experimental allergic encephalomyelitis) is the standard benchmark animal methodology for the study of MS. ReceptoPharm's drug, RPI-78M, proved to be very effective in preventing the onset of disability in acute and chronic models of the disease. The drug was also very effective in preventing the infiltration of immune cells into the central nervous system. This research was conducted to confirm the reported benefits of similar products in immune mediated diseases such as Multiple Sclerosis and Rheumatoid Arthritis.

"The EAE study yielded the results we expected though we were pleasantly surprised at the reduced CNS infiltration by lymphocytes," commented Paul Reid, PhD, CEO of ReceptoPharm. "The results of this study complete the rationale for entering into clinical trials for the MS indication. We are actively working on one IND for the Phase II/III AMN (Adrenomyeloneuropathy) indication and when that is completed we will be in a good position to enter into MS trials," he added.

The study was conducted by researchers in the Department of Anatomy and Cell Biology at the University of Saskatchewan. The lead researcher, Associate Professor Dr. Adel Mohamed, reported that the preliminary results indicate that RPI-78M inhibited the development of acute as well as the relapsing phases of the EAE in Lewis rats. The report also stated that, if confirmed, these preliminary results suggest that it is of interest to initiate clinical trials on MS patients using the drug. The conclusion of the report stated that it seems within the realm of possibility that RPI-78M may be as, if not more, therapeutically efficacious as the current interferon drugs in the treatment of neurologic disease.

"These results are very encouraging," commented Rik Deitsch, CEO of Nutra Pharma. "The positive results of the animal model as well as the strong findings from the microarray analysis support our move into Phase II human clinical trials," he added.

The final results of the EAE study are being submitted for journal publication and for presentation within the scientific community.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The results of ReceptoPharm's animal model using RPI-78M in Multiple Sclerosis should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News

Deprecated: mysql_connect(): The mysql extension is deprecated and will be removed in the future: use mysqli or PDO instead in /home/content/15/3443015/html/receptopharm/newsroom/data.php on line 12

Deprecated: Function split() is deprecated in /home/content/15/3443015/html/receptopharm/includes/recent_news.php on line 31
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
 
E-Alerts
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name:
Email:
NPC